Most Read

Situated in Frederick of Colorado, the advanced facility is engaged in the development and manufacturing of oligos that are short DNA and RNA molecules used for the creation

The agreement between Bristol Myers Squibb and Dragonfly Therapeutics includes DF6002, an extended half-life IL12 cytokine, which is being studied as a treatment for advanced solid tumours in

As per terms of the deal, Sanofi will purchase all of the outstanding shares of Principia by paying $100 per share in cash. Principia Biopharma is engaged in

The acceptance of IND will allow Enzychem to assess EC-18 in a phase 2 clinical study in patients with ARDS due to Covid-19. The EC-18 is originally obtained

Both companies have not disclosed the financial terms of the deal. The research will include the application of GeneCentric’s advanced RNA-based molecular profiling platform to illustrate the potential

According to the company, SAB-185 is a fully-human, specifically targeted, and broadly neutralising polyclonal antibody therapeutic candidate. Besides potentially treating Covid-19 patients, the drug candidate can provide protective

The acquisition of KaNDy Therapeutics will allow Bayer to expand its drug development pipeline in women’s healthcare. The deal also allows KaNDy Therapeutics to secure potential milestone payments

Under the deal, Ligand Pharmaceuticals will purchase all outstanding shares of Pfenex for $12 per share in cash or $438m in equity value on a fully diluted basis.

The deal between the firms allows Takeda Pharmaceutical to undertake the local production and commercialisation of NVX‑CoV2373 in Japan, which will be backed by funding from the Japanese